DK3024826T3 - NEW ISOINDOLINE OR ISOQUINOL COMPOUNDS, A PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Google Patents

NEW ISOINDOLINE OR ISOQUINOL COMPOUNDS, A PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Download PDF

Info

Publication number
DK3024826T3
DK3024826T3 DK14741648.1T DK14741648T DK3024826T3 DK 3024826 T3 DK3024826 T3 DK 3024826T3 DK 14741648 T DK14741648 T DK 14741648T DK 3024826 T3 DK3024826 T3 DK 3024826T3
Authority
DK
Denmark
Prior art keywords
methyl
carbonyl
phenyl
carboxamide
tetrahydroisoquinoline
Prior art date
Application number
DK14741648.1T
Other languages
Danish (da)
English (en)
Inventor
James Edward Paul Davidson
Paul Brough
I-Jen Chen
Mark Dodsworth
Imre Fejes
Nanteuil Guillaume De
Olivier Geneste
Anne-Françoise Guillouzic
Jean-Michel Henlin
Andras Kotschy
Diguarher Thierry Le
Arnaud Letiran
James Brooke Murray
Claire Walmsley
Johannes W G Meissner
Janos Tatai
Miklos Nyerges
Zoltan Szlavik
Jérome-Benoit Starck
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Application granted granted Critical
Publication of DK3024826T3 publication Critical patent/DK3024826T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
DK14741648.1T 2013-07-23 2014-07-22 NEW ISOINDOLINE OR ISOQUINOL COMPOUNDS, A PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DK3024826T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357276A FR3008977A1 (fr) 2013-07-23 2013-07-23 Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2014/065764 WO2015011164A1 (en) 2013-07-23 2014-07-22 New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
DK3024826T3 true DK3024826T3 (en) 2019-03-04

Family

ID=49911606

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14741648.1T DK3024826T3 (en) 2013-07-23 2014-07-22 NEW ISOINDOLINE OR ISOQUINOL COMPOUNDS, A PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Country Status (49)

Country Link
US (3) US9809574B2 (OSRAM)
EP (1) EP3024826B1 (OSRAM)
JP (1) JP6395829B2 (OSRAM)
KR (1) KR102008431B1 (OSRAM)
CN (2) CN109456324B (OSRAM)
AP (1) AP2016008989A0 (OSRAM)
AR (1) AR097009A1 (OSRAM)
AU (1) AU2014295101B2 (OSRAM)
BR (1) BR112016001080B1 (OSRAM)
CA (1) CA2919572C (OSRAM)
CL (1) CL2016000148A1 (OSRAM)
CR (1) CR20160030A (OSRAM)
CU (1) CU24352B1 (OSRAM)
CY (1) CY1121247T1 (OSRAM)
DK (1) DK3024826T3 (OSRAM)
DO (1) DOP2016000009A (OSRAM)
EA (1) EA032301B1 (OSRAM)
ES (1) ES2711371T3 (OSRAM)
FR (1) FR3008977A1 (OSRAM)
GE (2) GEP20207070B (OSRAM)
HK (1) HK1218754A1 (OSRAM)
HR (1) HRP20190277T1 (OSRAM)
HU (1) HUE041443T2 (OSRAM)
IL (1) IL243449A0 (OSRAM)
JO (1) JO3457B1 (OSRAM)
LT (1) LT3024826T (OSRAM)
MA (1) MA38801B1 (OSRAM)
MD (1) MD4793C1 (OSRAM)
ME (1) ME03346B (OSRAM)
MX (1) MX365373B (OSRAM)
MY (1) MY193619A (OSRAM)
NI (1) NI201600016A (OSRAM)
NZ (1) NZ716155A (OSRAM)
PE (1) PE20160241A1 (OSRAM)
PH (1) PH12016500034A1 (OSRAM)
PL (1) PL3024826T3 (OSRAM)
PT (1) PT3024826T (OSRAM)
RS (1) RS58344B1 (OSRAM)
RU (1) RU2689305C2 (OSRAM)
SA (1) SA516370439B1 (OSRAM)
SG (1) SG11201600205XA (OSRAM)
SI (1) SI3024826T1 (OSRAM)
TN (1) TN2016000003A1 (OSRAM)
TR (1) TR201819155T4 (OSRAM)
TW (1) TWI560184B (OSRAM)
UA (1) UA117490C2 (OSRAM)
UY (1) UY35664A (OSRAM)
WO (1) WO2015011164A1 (OSRAM)
ZA (1) ZA201600198B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA037300B1 (ru) 2016-04-20 2021-03-05 Бристол-Маерс Сквибб Компани Замещенные бициклические гетероциклические соединения
AU2019295765B2 (en) 2018-06-27 2024-08-29 Yumanity, Inc. Proteasome activity enhancing compounds
CA3158241A1 (en) * 2019-11-15 2021-05-20 Wuhan Ll Science And Technology Development Co., Ltd. Rock inhibitor and preparation method therefor and use thereof
CN112010796B (zh) * 2020-09-17 2022-04-22 浙江大学 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system
EP4313964A1 (en) * 2021-03-24 2024-02-07 Les Laboratoires Servier New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h )-carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds
JP2025508803A (ja) 2022-02-24 2025-04-10 レ ラボラトワール セルヴィエ 5-[7-(3,4-ジヒドロ-1h-イソキノリン-2-カルボニル)-1,2,3,4-テトラヒドロイソキノリン-6-イル]-1h-ピロール-3-カルボキサミド誘導体、それを含有する医薬組成物及びアポトーシス促進剤としてのその使用
PE20251072A1 (es) 2022-05-20 2025-04-10 Novartis Ag Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos
KR20250149173A (ko) * 2023-03-31 2025-10-15 미쓰이 가가쿠 가부시키가이샤 카바메이트 화합물
TW202540186A (zh) 2023-11-22 2025-10-16 瑞士商諾華公司 抗cd7抗體藥物結合物及其使用方法
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
WO2004096774A1 (en) 2003-05-01 2004-11-11 Glaxo Group Limited Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
US8557812B2 (en) * 2004-08-20 2013-10-15 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
CN101039662A (zh) * 2004-08-20 2007-09-19 密执安州立大学董事会 抗-细胞凋亡bcl-2家族成员的小分子抑制剂及其应用
RU2007128987A (ru) * 2005-02-15 2009-03-27 Ново Нордиск А/С (DK) 3,4-дигидро-1н-изохинолин-2-карбоновой кислоты 5-аминопиридин-2-2-иловые эфиры
ES2705599T3 (es) 2007-04-16 2019-03-26 Abbvie Inc Indoles sustituidos en la posición 7 como inhibidores de mcl-1
WO2009073545A2 (en) 2007-11-30 2009-06-11 Maxthera, Inc. Tetrahydro-isoquinoline ppat inhibitors as antibacterial agents
NZ587039A (en) 2008-02-13 2013-01-25 Gilead Connecticut Inc 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
US7984530B2 (en) 2008-02-14 2011-07-26 Tory Reynolds Pet waste vacuum system and apparatus, disposable liners therefor, and a method of collecting pet waste using same
JP2014521595A (ja) * 2011-05-25 2014-08-28 ブリストル−マイヤーズ スクイブ カンパニー 抗アポトーシスBcl阻害剤として有用な置換スルホンアミド
US9126979B2 (en) * 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EP2798432A4 (en) 2011-12-27 2015-07-22 Intel Corp METHODS AND SYSTEMS FOR CONTROLLING POWER SUPPLY NETWORKS DURING AN ACTIVE STATE OF A PERIODICALLY TRIGGERED DOMAIN IN ACCORDANCE WITH PERIODICALLY RELEASED DOMAIN LOADING CONDITIONS
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
MX365373B (es) 2019-05-31
MX2016000904A (es) 2016-04-25
FR3008977A1 (fr) 2015-01-30
RU2689305C2 (ru) 2019-05-27
PH12016500034B1 (en) 2016-03-28
PT3024826T (pt) 2019-01-28
IL243449A0 (en) 2016-02-29
SG11201600205XA (en) 2016-02-26
MA38801B1 (fr) 2019-03-29
CA2919572C (en) 2017-06-20
TW201504228A (zh) 2015-02-01
JP6395829B2 (ja) 2018-09-26
CN105431422B (zh) 2019-08-30
ME03346B (me) 2019-10-20
PH12016500034A1 (en) 2016-03-28
HK1218754A1 (zh) 2017-03-10
US9809574B2 (en) 2017-11-07
ES2711371T3 (es) 2019-05-03
AP2016008989A0 (en) 2016-01-31
RU2016106003A (ru) 2017-08-28
NZ716155A (en) 2019-05-31
JO3457B1 (ar) 2020-07-05
EP3024826B1 (en) 2018-11-14
MD4793B1 (ro) 2022-02-28
EP3024826A1 (en) 2016-06-01
MY193619A (en) 2022-10-20
CN105431422A (zh) 2016-03-23
US20160194304A1 (en) 2016-07-07
AU2014295101B2 (en) 2018-05-31
CR20160030A (es) 2016-03-09
MA38801A1 (fr) 2018-05-31
KR102008431B1 (ko) 2019-08-07
SA516370439B1 (ar) 2019-06-27
CY1121247T1 (el) 2020-05-29
US20200262816A1 (en) 2020-08-20
MD20160018A2 (ro) 2016-07-31
TWI560184B (en) 2016-12-01
NI201600016A (es) 2016-02-11
UA117490C2 (uk) 2018-08-10
SI3024826T1 (sl) 2019-03-29
TN2016000003A1 (en) 2017-07-05
DOP2016000009A (es) 2016-03-15
TR201819155T4 (tr) 2019-01-21
CU24352B1 (es) 2018-07-05
CA2919572A1 (en) 2015-01-29
MD4793C1 (ro) 2022-09-30
US20180002313A1 (en) 2018-01-04
EA201600122A1 (ru) 2016-07-29
CU20160010A7 (es) 2016-06-29
GEAP201914063A (en) 2019-10-25
GEP20207070B (en) 2020-02-25
PL3024826T3 (pl) 2019-05-31
RS58344B1 (sr) 2019-03-29
AR097009A1 (es) 2016-02-10
JP2016525529A (ja) 2016-08-25
HK1222856A1 (en) 2017-07-14
UY35664A (es) 2015-01-30
CL2016000148A1 (es) 2016-08-12
BR112016001080A2 (OSRAM) 2017-07-25
AU2014295101A1 (en) 2016-02-04
HUE041443T2 (hu) 2019-05-28
LT3024826T (lt) 2019-02-25
US11028070B2 (en) 2021-06-08
WO2015011164A1 (en) 2015-01-29
KR20160033224A (ko) 2016-03-25
PE20160241A1 (es) 2016-04-30
EA032301B1 (ru) 2019-05-31
US10689364B2 (en) 2020-06-23
ZA201600198B (en) 2019-07-31
CN109456324B (zh) 2022-04-22
HRP20190277T1 (hr) 2019-04-05
BR112016001080B1 (pt) 2022-04-05
CN109456324A (zh) 2019-03-12

Similar Documents

Publication Publication Date Title
US11028070B2 (en) Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
JP7086395B2 (ja) 置換インドールMcl-1阻害剤
ES2620515T3 (es) Nuevos derivados de pirrol, su procedimiento de preparación y composiciones farmacéuticas que los contienen
ES2687475T3 (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CN120265634A (zh) 三唑化合物、其制备方法和医药用途
BR112014018165B1 (pt) compostos de indolizina, seu processo de preparação, composições farmacêuticas, seus usos e sal de cloridrato
OA17896A (en) New compounds Isoindoline or Isoquinoline, process for their preparation and pharmaceutical compositions containing them.
HK1222856B (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them